Pharmacokinetics of Novel Dopamine Transporter Inhibitor CE-123 and Modafinil with a Focus on Central Nervous System Distribution

3Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

S-CE-123, a novel dopamine transporter inhibitor, has emerged as a potential candidate for cognitive enhancement. The objective of this study was to compare the tissue distribution profiles, with a specific focus on central nervous system distribution and metabolism, of S-CE-123 and R-modafinil. To address this objective, a precise liquid chromatography–high resolution mass spectrometry method was developed and partially validated. Neuropharmacokinetic parameters were assessed using the Combinatory Mapping Approach. Our findings reveal distinct differences between the two compounds. Notably, S-CE-123 demonstrates a significantly superior extent of transport across the blood–brain barrier (BBB), with an unbound brain-to-plasma concentration ratio (Kp,uu,brain) of 0.5, compared to R-modafinil’s Kp,uu,brain of 0.1. A similar pattern was observed for the transport across the blood–spinal cord barrier. Concerning the drug transport across cellular membranes, we observed that S-CE-123 primarily localizes in the brain interstitial space, whereas R-modafinil distributes more evenly across both sides of the plasma membrane of the brain’s parenchymal cells (Kp,uu,cell). Furthermore, our study highlights the substantial differences in hepatic metabolic stability, with S-CE-123 having a 9.3-fold faster metabolism compared to R-modafinil. In summary, the combination of improved BBB transport and higher affinity of S-CE-123 to dopamine transporters in comparison to R-modafinil makes S-CE-123 a promising candidate for further testing for the treatment of cognitive decline.

References Powered by Scopus

A cross-platform toolkit for mass spectrometry and proteomics

2692Citations
N/AReaders
Get full text

Cytochrome P450 and chemical toxicology

1328Citations
N/AReaders
Get full text

Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study

1080Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The Role of Dopamine Neurotransmitters in Neurological Diseases: New Sight

1Citations
N/AReaders
Get full text

Decoding neural circuit dysregulation in bipolar disorder: Toward an advanced paradigm for multidimensional cognitive, emotional, and psychomotor treatment

0Citations
N/AReaders
Get full text

Assessing central nervous system drug delivery

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Spreitzer, I., Keife, J., Strasser, T., Kalaba, P., Lubec, J., Neuhaus, W., … Loryan, I. (2023). Pharmacokinetics of Novel Dopamine Transporter Inhibitor CE-123 and Modafinil with a Focus on Central Nervous System Distribution. International Journal of Molecular Sciences, 24(23). https://doi.org/10.3390/ijms242316956

Readers over time

‘23‘240481216

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

75%

Researcher 1

25%

Readers' Discipline

Tooltip

Pharmacology, Toxicology and Pharmaceut... 3

50%

Design 1

17%

Neuroscience 1

17%

Engineering 1

17%

Article Metrics

Tooltip
Mentions
News Mentions: 1
Social Media
Shares, Likes & Comments: 19

Save time finding and organizing research with Mendeley

Sign up for free
0